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INTRODUCTION
Unrelated donor (URD) bone marrow transplantation
(BMT) can be curative therapy in a variety of malignant and
nonmalignant hematopoietic disorders [1]. However, many
patients of non-European heritage do not have access to appro-
priately matched donors [2]. Umbilical cord blood (UCB) is
being investigated as a new hematopoietic stem cell (HSC)
source [3] and, unlike BM, has the advantage of absence of any
risk to the donor. UCB transplantation (UCBT) has the poten-
tial to extend HSC transplantation to patients without HLA-
compatible BM donors or to those in need of an immediate
transplantation. In children, 0- to 3-antigen HLA-mismatch
is tolerated without an increase in graft-versus-host disease
(GVHD) or nonrelapse mortality [4], and UCBT is now being
investigated in adults [5]. A further advantage of UCBT is the
ability to obtain the UCB graft and proceed to transplantation
more quickly. To investigate access to URD HSC, we
reviewed our experience in terms of both success and speed of
obtaining URD UCB and BM grafts for pediatric and adult
patients during a 1-year period at the University of Minnesota.
METHODS
Patients and URD Grafts
All referrals for URD searches during 2000 were included
in this analysis. Patients were eligible for URD transplantation
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ABSTRACT
Unrelated donor (URD) umbilical cord blood (UCB) has several potential advantages over URD BM for hemato-
poietic stem cell transplantation. To examine the efficiency of donor identification for each of these URD stem cell
sources, we reviewed the search processes for all pediatric and adult URD transplantation referrals to the University
of Minnesota during a period of 1 year. Of 171 consecutive referrals for URD transplantation, 108 patients pro-
ceeded to a formal URD search with selection of at least 1 donor. Significantly more formal UCB searches (54%)
than BM searches (21%) were performed for patients who required urgent transplantation (P < .01). At least one
4-6/6 HLA-antigen matched UCB graft but no suitable BM graft was identified for 21 of the 108 patients (19%).
The median time required to obtain a URD BM donor (from formal search to clearance of a BM donor) was 49 days
(range, 32-293 days) compared to a UCB search time (from formal search to a donor unit chosen) of only 13.5 days
(range, 2-387 days). For patients undergoing both BM and UCB searches, 29 more days (95% confidence interval,
21-37 days) were required to identify and clear a URD BM donor than a UCB donor (P < .01). For the 76 patients
who proceeded to transplantation, patients receiving UCB received a transplant a median of 25 days more rapidly
than did those receiving BM (P < .01). These data confirm that the availability of banked cryopreserved URD UCB
grafts allows transplantations for patients with no available BM donor and that URD UCB grafts are available con-
siderably faster than are URD BM grafts. Faster availability is a particular advantage for patients requiring urgent
transplantation. These unique features of UCB transplantation must be considered in comparisons of the outcomes
of UCB versus BM transplant recipients and in the design of prospective trials comparing URD sources.
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if there were no available related donors matched for 5 or
6 HLA-A,B,DRB1 antigens. Patients were eligible for unre-
lated UCBT if HLA-compatible unrelated BM donors were
not available within 3 months of search initiation or if trans-
plantation was considered urgent. HLA-compatible BM
donors were deﬁned as at least a 5/6 HLA-A,B,DRB1 match,
unless the recipient was older than 35 years, in which case a
6/6 matched BM donor was required. UCB grafts were at
least 4/6 HLA-A,B,DRB1 matched and had a cryopreserved
cell dose of at least 1.5 × 107 nucleated cells (NC)/kg recipi-
ent body weight. Although the intent was to search for both
types of HSC simultaneously for all patients, whether or not
searches and donor selection were done for both types of
HSC depended on patient size, diagnosis, urgency of trans-
plantation, and available protocol. Urgent transplantations
were deﬁned as those needed as treatment for severe aplastic
anemia, acute leukemia beyond first remission, advanced
myelodysplasia, chronic myelogenous leukemia beyond
chronic phase, or any malignancy that by history was unstable
and unlikely to stay in remission for ≥3 months.
BM donors were identiﬁed through the National Mar-
row Donor Program (NMDP). UCB units were obtained
from the Placental Blood Programs at the New York Blood
Center, the St. Louis Cord Blood Bank, the Cord Blood
Transplantation Study, and through Netcord. HLA typing
was performed using the standard 2-stage complement-
dependent microcytotoxicity assay, and antigens were
assigned as deﬁned by the World Health Organization HLA
nomenclature committee. HLA-DRB1 type was determined
by hybridization of polymerase chain reaction–amplified
DNA with sequence-specific oligonucleotide probes with
sequencing if needed. High-resolution Class II typing
results for HLA-DRB1 were used to determine the selection
of all URD grafts. Treatment protocols for URD BMT and
UCBT were reviewed and approved by the Institutional
Review Board of the University of Minnesota. Written
informed consent was obtained from the patients prior to
formal URD search and transplantation.
Data Collection
Data collected for all patients included age, weight,
diagnosis, urgency of transplantation, and reason for selec-
tion of either BM or UCB. Search time was analyzed for all
patients by obtaining the dates of preliminary search, formal
search, and transplantation. For URD BM searches, the
dates that the donor was identified and that the donor
became available (ie, medically cleared and consent
obtained) were documented, whereas for URD UCB
searches, the date that the graft was chosen was recorded.
Statistical Analysis
The factors of age and weight were compared across
graft sources by the general Wilcoxon test. Analysis of differ-
ences in the percentage of urgent cases was carried out using
Pearson’s chi-square test. For comparison, the time to obtain
a URD graft was deﬁned as “formal search to donor avail-
able.” Dates for “donor identified” and “donor available”
were identical for UCB grafts, whereas for BM searches
“donor available” was the date of donor consent and medical
clearance (see Figure 2). The general Wilcoxon test was used
to compare search times between patients for whom only
one type of search was performed. For the patients who had
both URD BM and UCB searches, a paired t test was used to
compare the difference in search times [6].
RESULTS
URD Referrals
Between January 1 and December 31, 2000, 171 pedi-
atric and adult patients were referred for an allogeneic
transplantation and URD search (Figure 1). Sixty patients
did not proceed to a formal search and donor selection (rea-
sons summarized in Figure 1). A total of 108 patients pro-
ceeded to a formal search and selection of a speciﬁc donor:
either BM (ie, donor identiﬁed and cleared; n = 58) or UCB
(ie, donor identiﬁed; n = 33) donors, or both (ie, BM donor
identiﬁed and cleared and UCB also identiﬁed; n = 17).
UCB versus BM Searches
Further analysis of the search process for the 108 patients
undergoing formal search and donor selection, with the rea-
sons for the selection of either BM or UCB as stem cell
source, is summarized in Table 1. Of the 32 patients (30%)
that had both BM and UCB donors available to them but a
BM donor was pursued, only 7 patients required urgent
transplantation. Of the 24 patients (22%) for whom both
BM and UCB donors were identiﬁed but a UCB donor was
chosen, 16 required urgent transplantation. Twenty-one
patients (19%) had a UCB donor chosen because no URD
BM donor was identified. Overall, significantly more
Figure 1. Summary of referrals for allogeneic transplantation and URD searches during the year 2000 at the University of Minnesota.
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patients who required urgent transplantation underwent
UCB donor selection (54% of all UCB searches) compared
to BM donor selection (21% of all BM searches) (P < .01).
Speed of Obtaining URD Grafts
For patients who underwent a URD BM search and
donor selection (identification and clearance/consent), the
median time from formal search to availability of a BM
donor was 49 days (range, 32-293 days). The median time
from formal search to availability of a donor for all UCB
searches was 13.5 days (range, 2-387 days) (Figure 2). Analy-
sis of the search times for patients undergoing exclusively
BM or UCB donor selection revealed that a URD UCB
graft can be obtained in a signiﬁcantly shorter time than can
a URD BM graft (P < .01) and that the additional time taken
to obtain a BM donor was predominantly due to the addi-
tional 30-day interval (range, 10-101 days) required to clear
the donor. For patients who had both a BM donor cleared
and UCB chosen (n = 9), it took a mean of 29 more days
(95% confidence interval, 21-37 days) to secure the BM
donor than to secure the UCB donor (P < .01).
URD Transplantation
Characteristics of the 76 patients who proceeded to
URD transplantation (BMT, n = 42; UCBT, n = 34) are
summarized in Table 2. BMT recipients were older and
heavier than UCBT recipients. The majority of BMT recip-
ients received 6/6 HLA-matched grafts, whereas 97% of
UCBT recipients received grafts with 1 to 2 HLA-antigen
mismatches. The median infused cell dose for UCB recipi-
ents was 3.1 × 107 NC/kg (range, 1.2-19.0 × 107 NC/kg).
We next analyzed the speed at which patients could pro-
ceed to transplantation. Sixty-five percent of all UCBTs
were considered urgent versus 14% of BMTs (P < .01).
Although there were a greater number of urgent searches in
the UCBT group, the UCB and BM groups did not differ in
the time taken from the availability of the URD graft to
transplantation (29 days in BMT versus 31 days in UCBT,
P = NS). However, overall, patients proceeded to UCBT a
median of 25 days sooner than did BMT patients (P < .01).
Most of the additional time in the BMT group was due to
the additional month required to obtain clearance for BM
donation.
DISCUSSION
Availability of HLA-matched BM donors has been a
problem, particularly for minority ethnic groups. For exam-
ple, Caucasian patients are 30% more likely to ﬁnd a poten-
tial 6/6 HLA-matched BM donor through the NMDP than
are African American patients [2]. If extended matching of
recipient-donor pairs via high-resolution analysis of Class I
antigens proves valuable, this procedure may further limit
the success in identifying a suitable BM donor. In the current
report, we demonstrate that a signiﬁcant number of patients
referred to the University of Minnesota could be offered
HSC transplantation because they had access to URD UCB
when no appropriately matched URD BM donor was avail-
able. This greater access to URD UCB is possible because a
greater degree of HLA disparity can be tolerated in UCBT
without an increase in the incidence rates of GVHD and
nonrelapse mortality, at least in pediatric recipients [4]. It is
possible that if a population with an even higher representa-
tion of ethnic minority groups was similarly evaluated, the
proportion of patients with potential UCB but no matched
BM donors may be greater. Beatty et al. demonstrated that
Table 1. Reasons for Selection of BM versus UCB as Stem Cell Source
No. (%)
Formal search and donor selection 108
URD BM donor selected only 30 (28) 
(ineligible for UCBT protocols)
BM and UCB available/BM chosen per doctor 32 (30)
BM and UCB available/UCB chosen per doctor 24 (22)
UCB as no URD BM donor 21 (19)
BM donor available but no UCB 1 (1)
Figure 2. Comparison of time to identify and obtain a URD graft for 108 patients who underwent formal URD search and selection of a source of
URD HSC. Cryopreserved UCB grafts are available on the day of identiﬁcation. URD BM searches require the additional time to medically clear
and obtain the consent of the donor (donor identiﬁed to donor available).
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for some ethnic groups, such as African Americans, genetic
diversity is such that it will never be possible to create an
URD BM bank able to supply all patients with 6/6 matched
URD BM donors [7]. UCB offers a potential opportunity to
provide access to HSC for such minority patients.
The major current barrier to wider use of UCBT is the
problem of limited UCB cell dose. A proportion of patients
in this study had both UCB and BM available, and in some
instances of nonurgent transplantation, BM was selected
because of concerns about graft cell dose. As experience
with UCBT in adults increases, the lower limit of acceptable
UCB cell dose may become better deﬁned, and methods to
augment graft dose are likely to be developed. Interestingly,
we have noted an increase in the size of UCB units used for
transplantation at our institution over the last 2 years (data
not shown), likely because of the increased size of banks and
improved collection techniques. We are currently investi-
gating methods to overcome limited cell dose by infusion of
2 separate UCB units [8] or by ex vivo expansion.
This report details the experience of an institution that
has a high level of expertise in searching for both BM and
UCB grafts. This expertise is reﬂected in the greater speed
with which our patients obtained BM grafts and proceeded
to BMT, a median of 85 days compared to the median time
of 4 months across the NMDP network [2]. Nonetheless,
URD UCB has an advantage over BM in shortened search
time, and most importantly, UCB patients were able to
progress to transplantation approximately 1 month sooner
than were those receiving BMT. This result is consistent
with the ﬁndings of Rocha et al., who found in a retrospec-
tive study that the median time to transplantation was
4 weeks shorter for UCBT than for BMT [9]. The NMDP
has recently introduced a new strategy to speed the search
process for urgent URD BMT. This ultraurgent process
can currently identify 5-6/6 matched BM donors in a
median of 15 days from the start of the formal search (data
provided by the NMDP, 2001). However, donors must still
subsequently be cleared for donation, a process that
accounts for the bulk of the additional time taken to obtain
URD BM compared to UCB. Overall, UCB is likely to
maintain its speed advantage. As the size and efﬁciency of
UCB banks grow, UCB grafts may become obtainable even
faster than occurs currently.
In this study, we confirm that use of URD UCB can
extend the donor pool and that URD UCB grafts can be
obtained more quickly than URD BM. The speed advantage
of UCB may be of particular importance for those patients
requiring urgent transplantation. In this series, the more
rapid availability of UCB grafts resulted in a greater number
of urgent cases receiving URD UCBT rather than BMT.
This imbalance may be a potential bias when comparing
outcomes of URD BMT and UCBT. The difference in time
to obtain UCB and BM grafts will complicate a randomized
comparison between UCBT and BMT. Ultimately, this dif-
ference in availability may confound a deﬁnitive comparison
of the true merits of each HSC source.
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Table 2. Comparison of Patient Characteristics for Transplant Recipients 
(n = 76)
BMT (n = 42) UCBT (n = 34) P
Age, median (range), y 28.4 (1.1-62.4) 11.5 (0.7-64.8) .16
Weight, median (range), kg 67.0 (8-140) 45.8 (7.9-100) .05
Diagnosis, n (%)
Aplastic anemia 3 (7) 0 <.01
Hemoglobinopathy 0 1 (3)
Immune deficiency 0 2 (6)
Storage disease 11 (26) 3 (9)
Heme malignancy 24 (57) 28 (82)
Other 4 (10) 0
Disease status, n (%)
Advanced malignancy* 12/24 (50) 21/28 (71)
Race, n (%)
Caucasian 34 (81) 27 (79) NS
African American 1 (2) 1 (3)
Hispanic 1 (2) 2 (6)
Native American 0 1 (3)
Asian 1 (2) 1 (3)
Unknown 5 (12) 2 (6)
HLA disparity, n (%)
Match 33 (79) 1 (3) <.01
Mismatch 9 (21) 33 (97)
*Deﬁned as acute leukemias beyond the ﬁrst complete remission or
primary induction failures, chronic myelogenous leukemia post–blast
crisis, or any hematological malignancy in relapse or unresponsive to
chemotherapy.
